Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05981352
Other study ID # Pulpotomy of Primary Molars
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date October 2023
Est. completion date October 1, 2024

Study information

Verified date May 2023
Source Ain Shams University
Contact eman Ib Abdel Masoud, doctor
Phone 01555682322
Email eman.abdelmaksoud@dent.asu.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the current study is to evaluate and compare clinical and radiographic success and antibacterial effect of Hyaluronic Acid and Amniotic membrane pulpotomy in primary molars in comparison with MTA pulpotomy (Randomized Clinical Trial and In Vitro Study).


Description:

Pulpotomy is one of the most used frequently treatment for pulp involved in primary teeth. Pulpotomy is performed in a primary tooth with extensive caries but without evidence of radicular pathology when caries removal results in a carious or mechanical pulp exposure. It is a conservative therapy performed to remove the inflamed coronal pulp tissues followed by application of an effective and compatible bactericidal medicament. Many different compounds have been suggested include glutaraldehyde, electrosurgery, calcium hydroxide, ferric sulfate, freeze-dried bone, bone morphogenic proteins (BMP), mineral trioxide aggregate (MTA) and Bio dentine (Tricalcium Silicate Cement) as replacement for Form cresol in pulpotomy procedure however. Pulpotomy has been broadly classified as devitalization, preservation, and regeneration of the remaining pulp tissue. Other materials that has shown immense potential for regeneration like mineral trioxide aggregate (MTA). It is a biocompatible and bio inductive material that has been investigated for endodontic. Hyaluronic acid (HA) has recently emerged as a material of choice in preserving the vitality of the pulp. It is a natural mucopolysaccharide, carbohydrate polymer from the group of glycosaminoglycans. HA is synthetized on the cytoplasmic surface of plasma membranes and is common in humans and other vertebrates. It is the major component of the inner-cell cement of the capillary wall, and of the extracellular matrix of the connective tissue. Deposition of HA significantly increases during development, morphogenesis, wound repair and regeneration, malignancy, and inflammation. Hyaluronic acid (HA) or hyaluronan is a hydrated anionic polysaccharide plentiful in the extracellular matrix with a molecular weight of 4000-20,000,000 Da that is found in a variety of tissues including skin, synovial fluid, cartilage, tendons, eyes and embryonic mesenchyme . It is comprised of repeating disaccharides d-glucuronic acid and N-acetyl-d-glucosamine, which are joined together by alternating β-1,4 and β-1,3 glycoside bonding. During bone repair, it encourages the undifferentiated mesenchymal cells to migrate, adhere, and proliferate into osteoblastic cells. Due to its non-toxicity, biocompatibility, biodegradability and non-immunogenicity, and used in ophthalmology and orthopedics as an anti-inflammatory agent and anti bacterial agent. The use of a hyaluronic acid to cover a dentin defect, stimulated a cell-rich rearrangement of pulp tissue with few inflammatory cells, as well as being an acceptable and biocompatible scaffold for regenerating the dental pulp. Because of its high molecular weight when dissolved in water, hyaluronic acid's viscoelasticity increases, making it simpler to use as an injectable scaffold. Moreover, advantageous characteristics are related to the hyaluronic acid scaffolds as bioactivity, biocompatibility, biodegradability, in addition to serving as a reservoir for growth factors.. It is important to propose new biologically based therapeutics directed at preserving pulp vitality , forming biological tissue and neutralizing the side effects of previously used synthetically based biomaterials . Recently, novel biologically based materials have been developed from the placenta or other gestational tissues like the umbilical cord with highly rich stem cell reservoirs . Amniotic membrane (AM) is a fetes membranous sac forming the innermost layer of the placenta. It is a bi-layered membrane consists of amnion and chorion. Amnion consists of 3 distinct thin layers: an epithelial monolayer (closest to the fetes),a basement membrane and avascular mesenchymal stromal matrix (containing mesenchymal stem cells) that composed of 3 adjacent but distinct layers: outermost spongy, middle fibroblastic and inner compact. Although it is a thin membrane (70-180 μm thick), it is remarkably elastic and strong natural biological barricade protecting the fetus from trauma and bacterial infection . In contrast, the chorion is 3-4 times thicker than amnion and consists of a reticular, basement membrane, and trophoblastic layers. Both membranes play important roles in embryo's overall development, embryo's nourishment and breathing . Amniotic membrane matrix contains plenteous growth factors (GFs) including basic-fibroblast growth factor (b-FGF), nidogen growth factor (NGF), keratinocyte growth factor (KGF), epidermal derived growth factor (EDGF), and transforming GF-beta growth factor (TGF-β) which promote tissue regeneration . These GFs mimic the stem cell niche for ex vivo growth and provide a natural healing environment. It acts as a structural scaffold supporting proliferation, differentiation, and regeneration due to presence of fibronectin, laminins, proteoglycans, collagen types I, III, IV, V and VI, elastin, nidogen, and hyaluronic acid in its stromal layer, and act as an excellent candidature for a native scaffold in tissue engineering . Furthermore, it secretes nutrient factors , promotes cell migration, adhesion, differentiation, and suppresses the semi allogenic immune response against the foetus . In addition, it has a biological, anti-inflammatory (similar to cortisone and steroids shots), anti-fibrotic, anti-microbial (including beta-defensins), anti-scarring, anti-angiogenic and analgesic properties that make it a unique therapy for wound care and ideal substrate for supporting the growth of mesenchymal progenitor cells via prolonging their lifespan It is used in allotransplant due to its ability to promote cellular growth and attachment with the lack of its immunogenicity and toxicity; it was first reported by Davis since 1910 in skin transplantation. Also, it has been used successfully for over a decade in a wide range of surgical application, biological wound dressing, ophthalmic reconstructive surgery, an adhesion barrier in the spine, and in-ear and orthopedic surgery. It is easily obtained, processed, transported, and prepared in different forms for clinical use like fresh, dried, frozen, freeze derived irradiated, stabilized amniotic and cryopreserved membranes . Amnion-based products have a proven rate of success in the field of dentistry since 1990s, when first demonstrated safety and efficacy in pre-and clinical studies . The dehydrated or cryopreserved membrane is used for retaining the majority of the natural (fibrillar and membranous) collagens, maintaining the composition of GFs and bioactive molecules found in natural and unprocessed placental tissues, and increasing stability and shelf life of the product .


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 36
Est. completion date October 1, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years to 8 Years
Eligibility Inclusion Criteria: - Patients aged from 4 to 8 years old. - Patients who are free from ant medical condition. - Patients who have a vital deep carious Mandibular primary molar which is indicated for pulpotomy . - No clinical signs or symptoms of irreversible pulpitis as pain on percussion, tooth mobility, presence of sinus or fistula, history of swelling , Spontaneous pain. - No radiographic evidence of any periapical pathosis , Internal or external root resorption , Absence of discontinuity of lamina dura . - Physiological root resorption not more than 1/3 of crown Exclusion Criteria: - Teeth that are badly broken down, that cannot be restored. - Presence of uncontrolled bleeding after pulpotomy - Patients/ parent guardians that refuse to sign informed consent.

Study Design


Intervention

Procedure:
mineral trioxide aggregate pulpotomy
After achieving hemostats, Mineral trioxide aggregate powder will be mixed with saline. Then Mineral trioxide aggregate will be placed directly on the pulp stumps.
Dehydrated amniotic membrane pulpotomy
After achieving haemostasis, a double layer of sterile processed human allograft tis¬sue (dehydrated dual-layer dental amni¬on patch) will be trimed and soaked in saline for a minute. Dehydrated amniotic membrane will be Placed directly on the pup stumps using sterile tweezers and adjust¬ed to the entire floor of the pulp chamber.
Hyaluronic acid pulpotomy
After achieving haemostasis, pulp stumps will be covered with a mixture of Hyaluronic acid gel and zinc oxide powder with consistency (1:1 ratio by volume) . The cavities of all pulpotomy molars will be sealed with a layer of reinforced zinc oxide and eugenol .

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Outcome

Type Measure Description Time frame Safety issue
Primary clinical pulp testing pulp testing clinically measured by zurn and seale criteria , 0 baseline , changes from baseline pulp condition at 3 month, change from the baseline pulp condition at 6 month, change from baseline pulp condition at 9 month, change from base line pulp condition at 12 month.
Primary Radio graphic pulp testing pulp testing radio graphic measured by digital radio graph parallel technique 0 baseline , changes from baseline pulp condition at 3 month, change from the baseline pulp condition at 6 month, change from baseline pulp condition at 9 month, change from base line pulp condition at 12 month.
See also
  Status Clinical Trial Phase
Recruiting NCT06227390 - Clinical and Radiographic Outcomes of Partial Pulpotomy Procedure in Primary Molars Utilizing Different Capping Materials and Different Restorative Methods N/A
Completed NCT06398327 - Efficacy Of Proinflammatory Cytokines in The Primary Molar Pulpotomy N/A
Recruiting NCT03883295 - Evaluation of Clinical and Radiological Success of Vital Amputation Treatment N/A
Active, not recruiting NCT03580135 - Postoperative Pain Evaluation of Mineral Trioxide Aggregate and Propolis After Pulpotomy in Carious Primary Molars Phase 2
Recruiting NCT03410134 - Assessment of Vital Pulp Therapy in Permanent Molars N/A
Recruiting NCT04793477 - Effectiveness of Rotating System and Single File Reciprocating System in Temporal Molars N/A
Completed NCT04274920 - Dentin Bridge Formation After Indirect Pulp Capping With Bioactive Glass Incorporated in Resin Composite and Its Adhesive in Comparison With Light Cured Calcium Hydroxide N/A
Not yet recruiting NCT05839548 - Articaine Efficacy and Safety for 3 Years Old Children Phase 3
Active, not recruiting NCT05912907 - Potassium Nitrate in Polycarboxylate as a Direct Pulp Capping N/A
Completed NCT05633537 - Clinical & Radiographic Evaluation of Zinc Oxide-Ozonated Oil as a New Primary Root Canal Filling N/A
Completed NCT06110494 - A New Clinical Use of Ferumoxytol Nanoparticles: An Antibiofilm Treatment Phase 4
Completed NCT03542019 - Survival of Endocrowns Made From Different Ceramics N/A
Completed NCT06002646 - Lasers as an Alternative to Formocresol and Sodium Hypochlorite Medicaments in Pulpotomy Techniques Phase 4
Not yet recruiting NCT03368391 - : Pulpal Blood Flow With the Use of Intra-nasal Anesthetic Phase 4
Recruiting NCT06196515 - Anti-bacterial Potential of Nano Calcium Hydroxide as an Intracanal Medication Phase 2/Phase 3
Not yet recruiting NCT04650113 - Clinical and Radiographic Assessment of Partial and Complete Pulpotomy in Primary Molars Using MTA Phase 1/Phase 2
Completed NCT06129643 - Post-operative Pain After Laser Root Canal Treatment of Necrotic Teeth With Apical Periodontitis Phase 2
Recruiting NCT06207253 - The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament Phase 2/Phase 3
Completed NCT03582319 - Clinical and Radiographic Evaluation of Biodentine Versus Formocresol N/A
Not yet recruiting NCT06170775 - Sodiumhexametaphosphate as Pulp Capping Material for Primary Teeth N/A